Compare Intuitive Surgical, Inc. (ISRG) vs Summit Therapeutics Inc (SMMT) Price & Performance

Intuitive Surgical (ISRG) trades at $350.06, down 1.34% on the day and near its 52-week low of $344.55. The stock is in a bearish technical trend despite strong fundamentals: Q2 2026 EPS beat estimates at $2.80 vs. $2.48 expected, revenue grew to $10.06B in 2025, and net income margin expanded to 28.45%. However, slowing U.S. procedure growth and a cautious 2026 outlook have pressured shares, with recent news highlighting a nearly 40% decline year-to-date.

The outlook remains mixed: robust profitability and a 69.6% analyst buy rating with a $504.56 consensus target suggest long-term value, but near-term risks include valuation concerns (P/E 40.5), competitive pressures, and macroeconomic headwinds. Investors face a divergence between solid execution and market sentiment driven by growth deceleration fears.

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.

The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.